A trial of N17350 injected into tumors for advanced solid cancers
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor that has progressed on or is not eligible for standard treatments.
- You must have a tumor that can be safely injected with the study drug, either near the skin's surface or deep inside the body.
- You must be willing to have a tumor biopsy before and during the study, if safe and possible.
- You must be generally active and able to care for yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GV20-0251 combined with an immunotherapy (anti-PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests a new drug that may help people with advanced solid tumors that have not responded to other treatments. The drug is given as an injection and aims to stop cancer growth.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.